Navigation Links
Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Date:9/25/2007

lity of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our Web sites: http://www.rocheusa.com or http://www.roche.us.

(1) Cassidy J, et al. Annals of Oncology 2002; 13: 566-575

(2) Blum J, et al. Cancer 2001; 92(7): 1759-1768


'/>"/>
SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Negative Pressure Wound Devices Draw FDA Notice, Advice 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Social Security Disability Advocacy Firm Changes Name to 26quot 3BFreedom Disability 26quot 3B and Acquires 22 000 Square Foot Corporate Hea 51035 1National Social Security Disability Advocacy Firm Changes Name to 26quot 3BFreedom Disability 26quot 3B and Acquires 22 000 Square Foot Corporate Hea 51035 2National Social Security Disability Advocacy Firm Changes Name to 26quot 3BFreedom Disability 26quot 3B and Acquires 22 000 Square Foot Corporate Hea 51035 3Cellular Dynamics International Reprograms Blood Cells into Stem Cells 12932 1Cellular Dynamics International Reprograms Blood Cells into Stem Cells 12932 2Affinity VideoNet Partners With Providea Conferencing 51028 1Affinity VideoNet Partners With Providea Conferencing 51028 2Affinity VideoNet Partners With Providea Conferencing 51028 3